These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 23221565)

  • 61. HIV-1 VRC01 Germline-Targeting Immunogens Select Distinct Epitope-Specific B Cell Receptors.
    Lin YR; Parks KR; Weidle C; Naidu AS; Khechaduri A; Riker AO; Takushi B; Chun JH; Borst AJ; Veesler D; Stuart A; Agrawal P; Gray M; Pancera M; Huang PS; Stamatatos L
    Immunity; 2020 Oct; 53(4):840-851.e6. PubMed ID: 33053332
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Anti-HIV B Cell lines as candidate vaccine biosensors.
    Ota T; Doyle-Cooper C; Cooper AB; Huber M; Falkowska E; Doores KJ; Hangartner L; Le K; Sok D; Jardine J; Lifson J; Wu X; Mascola JR; Poignard P; Binley JM; Chakrabarti BK; Schief WR; Wyatt RT; Burton DR; Nemazee D
    J Immunol; 2012 Nov; 189(10):4816-24. PubMed ID: 23066156
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Comparison of HIV Type 1 ADA gp120 monomers versus gp140 trimers as immunogens for the induction of neutralizing antibodies.
    Kim M; Qiao ZS; Montefiori DC; Haynes BF; Reinherz EL; Liao HX
    AIDS Res Hum Retroviruses; 2005 Jan; 21(1):58-67. PubMed ID: 15665645
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Electron microscopic and immunochemical analysis of the broadly neutralizing HIV-1-specific, anti-carbohydrate antibody, 2G12.
    Roux KH; Zhu P; Seavy M; Katinger H; Kunert R; Seamon V
    Mol Immunol; 2004 Aug; 41(10):1001-11. PubMed ID: 15302162
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Cross-subtype neutralizing antibodies induced in baboons by a subtype E gp120 immunogen based on an R5 primary human immunodeficiency virus type 1 envelope.
    VanCott TC; Mascola JR; Loomis-Price LD; Sinangil F; Zitomersky N; McNeil J; Robb ML; Birx DL; Barnett S
    J Virol; 1999 Jun; 73(6):4640-50. PubMed ID: 10233923
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Targeting the carbohydrates on HIV-1: Interaction of oligomannose dendrons with human monoclonal antibody 2G12 and DC-SIGN.
    Wang SK; Liang PH; Astronomo RD; Hsu TL; Hsieh SL; Burton DR; Wong CH
    Proc Natl Acad Sci U S A; 2008 Mar; 105(10):3690-5. PubMed ID: 18310320
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Anti-V3/Glycan and Anti-MPER Neutralizing Antibodies, but Not Anti-V2/Glycan Site Antibodies, Are Strongly Associated with Greater Anti-HIV-1 Neutralization Breadth and Potency.
    Jacob RA; Moyo T; Schomaker M; Abrahams F; Grau Pujol B; Dorfman JR
    J Virol; 2015 May; 89(10):5264-75. PubMed ID: 25673728
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Induction of Heterologous Tier 2 HIV-1-Neutralizing and Cross-Reactive V1/V2-Specific Antibodies in Rabbits by Prime-Boost Immunization.
    Townsley S; Mohamed Z; Guo W; McKenna J; Cleveland B; LaBranche C; Beaumont D; Shen X; Yates NL; Pinter A; Tomaras GD; Ferrari G; Montefiori DC; Hu SL
    J Virol; 2016 Oct; 90(19):8644-60. PubMed ID: 27440894
    [TBL] [Abstract][Full Text] [Related]  

  • 69. mRNA-LNP HIV-1 trimer boosters elicit precursors to broad neutralizing antibodies.
    Xie Z; Lin YC; Steichen JM; Ozorowski G; Kratochvil S; Ray R; Torres JL; Liguori A; Kalyuzhniy O; Wang X; Warner JE; Weldon SR; Dale GA; Kirsch KH; Nair U; Baboo S; Georgeson E; Adachi Y; Kubitz M; Jackson AM; Richey ST; Volk RM; Lee JH; Diedrich JK; Prum T; Falcone S; Himansu S; Carfi A; Yates JR; Paulson JC; Sok D; Ward AB; Schief WR; Batista FD
    Science; 2024 May; 384(6697):eadk0582. PubMed ID: 38753770
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Toward a carbohydrate-based HIV-1 vaccine: synthesis and immunological studies of oligomannose-containing glycoconjugates.
    Ni J; Song H; Wang Y; Stamatos NM; Wang LX
    Bioconjug Chem; 2006; 17(2):493-500. PubMed ID: 16536482
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Characterization of the outer domain of the gp120 glycoprotein from human immunodeficiency virus type 1.
    Yang X; Tomov V; Kurteva S; Wang L; Ren X; Gorny MK; Zolla-Pazner S; Sodroski J
    J Virol; 2004 Dec; 78(23):12975-86. PubMed ID: 15542649
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Defining carbohydrate antigens as HIV vaccine candidates.
    Pashov A; Perry M; Dyar M; Chow M; Kieber-Emmons T
    Curr Pharm Des; 2007; 13(2):185-201. PubMed ID: 17269927
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Monoclonal Antibodies, Derived from Humans Vaccinated with the RV144 HIV Vaccine Containing the HVEM Binding Domain of Herpes Simplex Virus (HSV) Glycoprotein D, Neutralize HSV Infection, Mediate Antibody-Dependent Cellular Cytotoxicity, and Protect Mice from Ocular Challenge with HSV-1.
    Wang K; Tomaras GD; Jegaskanda S; Moody MA; Liao HX; Goodman KN; Berman PW; Rerks-Ngarm S; Pitisuttithum P; Nitayapan S; Kaewkungwal J; Haynes BF; Cohen JI
    J Virol; 2017 Oct; 91(19):. PubMed ID: 28701403
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Crystal structure of the HIV neutralizing antibody 2G12 in complex with a bacterial oligosaccharide analog of mammalian oligomannose.
    Stanfield RL; De Castro C; Marzaioli AM; Wilson IA; Pantophlet R
    Glycobiology; 2015 Apr; 25(4):412-9. PubMed ID: 25380763
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Structural Comparison of Human Anti-HIV-1 gp120 V3 Monoclonal Antibodies of the Same Gene Usage Induced by Vaccination and Chronic Infection.
    Chan KW; Pan R; Costa M; Gorny MK; Wang S; Lu S; Kong XP
    J Virol; 2018 Sep; 92(18):. PubMed ID: 29997214
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Immunogenicity of a Prefusion HIV-1 Envelope Trimer in Complex with a Quaternary-Structure-Specific Antibody.
    Cheng C; Pancera M; Bossert A; Schmidt SD; Chen RE; Chen X; Druz A; Narpala S; Doria-Rose NA; McDermott AB; Kwong PD; Mascola JR
    J Virol; 2015 Dec; 90(6):2740-55. PubMed ID: 26719262
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Reactivity-based one-pot synthesis of oligomannoses: defining antigens recognized by 2G12, a broadly neutralizing anti-HIV-1 antibody.
    Lee HK; Scanlan CN; Huang CY; Chang AY; Calarese DA; Dwek RA; Rudd PM; Burton DR; Wilson IA; Wong CH
    Angew Chem Int Ed Engl; 2004 Feb; 43(8):1000-3. PubMed ID: 14966891
    [No Abstract]   [Full Text] [Related]  

  • 78. Antibodies against Manalpha1,2-Manalpha1,2-Man oligosaccharide structures recognize envelope glycoproteins from HIV-1 and SIV strains.
    Luallen RJ; Agrawal-Gamse C; Fu H; Smith DF; Doms RW; Geng Y
    Glycobiology; 2010 Mar; 20(3):280-6. PubMed ID: 19920089
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Glycosylation Benchmark Profile for HIV-1 Envelope Glycoprotein Production Based on Eleven Env Trimers.
    Go EP; Ding H; Zhang S; Ringe RP; Nicely N; Hua D; Steinbock RT; Golabek M; Alin J; Alam SM; Cupo A; Haynes BF; Kappes JC; Moore JP; Sodroski JG; Desaire H
    J Virol; 2017 May; 91(9):. PubMed ID: 28202756
    [TBL] [Abstract][Full Text] [Related]  

  • 80. HIV-1 broadly neutralizing antibody precursor B cells revealed by germline-targeting immunogen.
    Jardine JG; Kulp DW; Havenar-Daughton C; Sarkar A; Briney B; Sok D; Sesterhenn F; Ereño-Orbea J; Kalyuzhniy O; Deresa I; Hu X; Spencer S; Jones M; Georgeson E; Adachi Y; Kubitz M; deCamp AC; Julien JP; Wilson IA; Burton DR; Crotty S; Schief WR
    Science; 2016 Mar; 351(6280):1458-63. PubMed ID: 27013733
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.